We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Regeneron Pharmaceuticals has sued Viatris over the company’s proposed biosimilar of Regeneron’s blockbuster vision loss drug, saying it violates multiple patents. Read More
Pfizer announced that it will pay $5.4 billion for Global Blood Therapeutics (GBT), manufacturer of Oxbryta (voxelotor), one of a handful of drugs for treating sickle cell anemia. Read More
Amgen announced that it is acquiring ChemoCentryx, a developer of oral therapies to treat autoimmune diseases, inflammatory disorders and cancer, for approximately $3.7 billion. Read More
Johnson & Johnson (J&J) disclosed that it has pursued arbitration against beleaguered vaccine manufacturer Emergent BioSolutions for alleged breach of contract. Read More
Vertex Pharmaceuticals has doubled down on its patent fight against Lupin over the company’s plan to market a generic version of Vertex’s cystic fibrosis treatment Kalydeco (ivacaftor). Read More
Kelun-Biotech will receive an upfront payment of $35 million and is eligible to receive future milestone payments totaling up to $901 million. Read More
Amneal Pharmaceuticals subsidiary Impax Laboratories has agreed to pay $145 million to settle allegations it partnered with Endo International to illegally delay the launch of a generic of Endo’s opioid painkiller Opana ER (oxymorphone). Read More